These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 17023498)

  • 1. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.
    Braithwaite RS; Shechter S; Roberts MS; Schaefer A; Bangsberg DR; Harrigan PR; Justice AC
    J Antimicrob Chemother; 2006 Nov; 58(5):1036-43. PubMed ID: 17023498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
    Kozal MJ; Hullsiek KH; Macarthur RD; Berg-Wolf Mv; Peng G; Xiang Y; Baxter JD; Uy J; Telzak EE; Novak RM;
    HIV Clin Trials; 2007; 8(6):357-70. PubMed ID: 18042501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy.
    d'Ettorre G; Forcina G; Ceccarelli G; Andreotti M; Andreoni C; Rizza C; Massetti AP; Sarmati L; Mastroianni CM; Vella S; Andreoni M; Vullo V
    J Chemother; 2011 Feb; 23(1):24-7. PubMed ID: 21482490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the rate of accumulating drug resistance mutations in the HIV genome.
    Braithwaite RS; Shechter S; Chang CC; Schaefer A; Roberts MS
    Value Health; 2007; 10(3):204-13. PubMed ID: 17532813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.
    Raffa JD; Tossonian HK; Grebely J; Petkau AJ; DeVlaming S; Conway B
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):397-9. PubMed ID: 18398974
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic.
    Klibanov OM; Dolder CR; Assefa F; Ekwonu TJ
    AIDS Patient Care STDS; 2013 Apr; 27(4):205-7. PubMed ID: 23514132
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adherence and resistance].
    Klimkait T; Vernazza P
    Ther Umsch; 2004 Oct; 61(10):631-4. PubMed ID: 15532193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
    Garvie PA; Lensing S; Rai SN
    Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy: treatment-experienced individuals.
    Calvo KR; Daar ES
    Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients.
    Maggiolo F; Airoldi M; Kleinloog HD; Callegaro A; Ravasio V; Arici C; Bombana E; Suter F
    HIV Clin Trials; 2007; 8(5):282-92. PubMed ID: 17956829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
    J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
    Sethi AK; Celentano DD; Gange SJ; Moore RD; Gallant JE
    Clin Infect Dis; 2003 Oct; 37(8):1112-8. PubMed ID: 14523777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.